Table 1.
Baseline features of 58 anti-MPO-ILD patients.
| n | % | |
|---|---|---|
| Sex M/F | 27/31 | 46.6/53.4 |
| Smoking history | 23 | 39.7 |
| ILD pattern | ||
| UIP | 30 | 51.7 |
| NSIP | 11 | 19.0 |
| OP | 4 | 6.9 |
| Mixed pattern | 13 | 22.4 |
| Median | IQR | |
| Age at ILD diagnosis | 69 | 9 |
| Follow-up duration (months) | 39.0 | 51 |
| FVC baseline (%) | 84 | 28.25 |
| FVC end follow-up (%) | 80 | 29 |
| DLCO baseline (%) | 55 | 27.0 |
| DLCO end follow-up (%) | 49 | 36.0 |
Anti-MPO: anti-myeloperoxidase antibodies; ILD: interstitial lung disease; M: males; F: females; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; FVC: forced vital capacity; DLCO: diffusion lung capacity for CO; IQR: interquartile range.